

# Perturbation of *Hoxb5* signaling in vagal and trunk neural crest cells causes apoptosis and neurocristopathies in mice

MKM Kam<sup>1</sup>, MCH Cheung<sup>2,3</sup>, JJ Zhu<sup>1</sup>, WWC Cheng<sup>1</sup>, EWY Sat<sup>1</sup>, PKH Tam<sup>1,3</sup> and VCH Lui<sup>1,3</sup>

Neural crest cells (NCCs) migrate from different regions along the anterior–posterior axis of the neural tube (NT) to form different structures. Defective NCC development causes congenital neurocristopathies affecting multiple NCC-derived tissues in human. Perturbed *Hoxb5* signaling in vagal NCC causes enteric nervous system (ENS) defects. This study aims to further investigate if perturbed *Hoxb5* signaling in trunk NCC contributes to defects of other NCC-derived tissues besides the ENS. We perturbed *Hoxb5* signaling in NCC from the entire NT, and investigated its impact in the development of tissues derived from these cells in mice. Perturbation of *Hoxb5* signaling in these NCC resulted in *Sox9* downregulation, NCC apoptosis, hypoplastic sympathetic and dorsal root ganglia, hypopigmentation and ENS defects. Mutant mice with NCC-specific *Sox9* deletion also displayed some of these phenotypes. *In vitro* and *in vivo* assays indicated that the *Sox9* promoter was bound and trans-activated by *Hoxb5*. *In ovo* studies further revealed that *Sox9* alleviated apoptosis induced by perturbed *Hoxb5* signaling, and *Hoxb5* induced ectopic *Sox9* expression in chick NT. This study demonstrates that *Hoxb5* regulates *Sox9* expression in NCC and disruption of this signaling causes *Sox9* downregulation, NCC apoptosis and multiple NCC-developmental defects. Phenotypes such as ENS deficiency, hypopigmentation and some of the neurological defects are reported in patients with Hirschsprung disease (HSCR). Whether dysregulation of *Hoxb5* signaling and early depletion of NCC contribute to ENS defect and other neurocristopathies in HSCR patients deserves further investigation.

*Cell Death and Differentiation* (2014) 21, 278–289; doi:10.1038/cdd.2013.142; published online 18 October 2013

Neural crest cells (NCCs) are generated from the dorsal neural tube (NT), migrate to the periphery and give rise to diverse cell lineages in many tissues according to the anterior–posterior (A–P) level of the NT from which they originate.<sup>1–3</sup> Cranial NCCs differentiate into teeth, bone, cartilage and connective tissue in the head; vagal NCCs contribute to the enteric nervous system (ENS) and cardiac outflow tracts; trunk NCCs give rise to sympathetic ganglia and norepinephrine-producing cells in the adrenal gland; sacral NCC contributes to the ENS of distal gut.<sup>4–9</sup> Skin pigment cells are derived from NCC from all A–P levels. Defective NCC development causes neurocristopathies.

*Hox* genes encode transcription factors with a DNA-binding homeodomain that recognizes a specific sequence and thereby mediates transcriptional regulation of target genes in numerous developmental processes. In mammals, 39 *Hox* genes are separated into four clusters *Hoxa*, *Hoxb*, *Hoxc* and *Hoxd*, on four different chromosomes. *Hox* genes are subdivided into 13 paralogous groups, and these *Hox* genes are expressed in overlapping domains with spatially staggered anterior expression boundaries along the NT.<sup>10–13</sup>

The different combinations of *Hox* genes expressed in these domains are mirrored in the NCC derived from those domains.<sup>14–16</sup> So far, our knowledge regarding the role of *Hox* genes during NCC development comes mostly from loss-of-function experiments, however, the overlapping expression and extensive functional redundancy among *Hox* genes preclude detailed investigations of the developmental functions of individual *Hox* genes in this way.

Among the *Hox* genes expressed in the developing gut, *Hoxb5* expression pattern is intimately associated with vagal NCC and ENS development.<sup>17–24</sup> Deletion of *Hoxb5* caused a rostral shift of the shoulder girdle in mice, implying a patterning role of *Hoxb5* in specifying the position of limbs on the body axis.<sup>25</sup> However, no abnormal development was observed in NCC or other tissues that express *Hoxb5*, probably due to functional redundancy among paralogous *Hox* members with overlapping expression domains.

To circumvent the problem of functional redundancy and investigate the function of *Hoxb5* in NCC, we generated transgenic mice that express a dominant-negative chimeric protein, engrailed-*Hoxb5* (*enb5*), upon Cre-induction.

<sup>1</sup>Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; <sup>2</sup>Department of Biochemistry, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China and <sup>3</sup>Centre for Reproduction, Development and Growth, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China

\*Corresponding author: VCH Lui, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China. Tel: +(852)28199607; Fax: +(852)28199621; E-mail: vchlui@hkucc.hku.hk

**Keywords:** *Hoxb5*; neural crest cells; neurocristopathies; *Sox9*

**Abbreviations:** NCC, neural crest cell; A–P, anterior–posterior; ENS, enteric nervous system; *enb5*, engrailed-*Hoxb5*; NT, neural tube; X-gal, beta-galactosidase; DRG, dorsal root ganglion; Dct, dopachrome tautomerase; E, embryonic day; GST, glutathione S-transferase; ChIP, chromatin immunoprecipitation; PCR, polymerase chain reaction; CNS, central nervous system; HSCR, Hirschsprung disease

Received 17.4.13; revised 30.7.13; accepted 12.9.13; Edited by RA Knight; published online 18.10.2013

This *enb5* repressor competes with *Hoxb5* for binding to target genes, thereby disrupting the developmental pathways that require *Hoxb5*. Using these mice, we previously showed that blocking *Hoxb5* signaling in vagal NCC causes reduced *Ret* expression, retarded NCC migration and ENS defects,<sup>22</sup> indicating that *Hoxb5* regulates vagal NCC and ENS development.

*Hoxb5* is also expressed in trunk NCC. To investigate whether *Hoxb5* regulates trunk NCC development, in this study we crossed *enb5* mice with *Wnt1-Cre* mice to induce *enb5* expression in NCC from the full length of the NT, and looked for NCC abnormalities. We showed that *Hoxb5* regulates the expression of *Sox9* in trunk NCC, and that perturbation of *Hoxb5* signaling in NCC causes downregulation of *Sox9*, apoptosis of NCC and neurocristopathies in mice.

## Results

**Hoxb5 perturbation in NCC causes developmental defects.** To investigate the function of *Hoxb5* in NCC derived from the entire A–P axis of the NT, we crossed *enb5* mice with *Wnt1-Cre* mice.<sup>26</sup> This induced the expression of *enb5* protein, perturbing *Hoxb5* function in NCC derived from all along the NT. We then studied the effects on the development of NCC and NCC-derived structures.

To trace NCC in *Wnt1-Cre/enb5* mice, we used *Rosa26R* (*R26R*) Cre activity-reporter mice in our crosses. At E9.0, beta-galactosidase (X-gal)-positive cells were located in the midbrain, frontal-nasal region, first and second branchial arches in both *Wnt1-Cre/R26R* and *Wnt1-Cre/R26R/enb5* (Figure 1a). By E9.5, X-gal-positive cells were also detected in the hindbrain, third and fourth branchial arches, circumpharyngeal ridge, frontal-nasal process and the entire NT. As the embryos developed further, more X-gal-positive cells were found populating the midbrain, hindbrain, NT and NCC-derived structures including the branchial arches, dorsal root ganglion (DRG), sympathetic ganglion and the frontal-nasal region at E10.5. X-gal-positive NCC populated similar regions in *Wnt1-Cre/R26R* and *Wnt1-Cre/R26R/enb5* embryos; however, the intensity of X-gal staining in the NT, DRG and sympathetic ganglion was generally weaker in the *Wnt1-Cre/R26R/enb5* embryos, indicating that fewer X-gal-positive cells were present.

At the trunk level (just distal to forelimb) of E12.5 *Wnt1-Cre/R26R* embryos, X-gal-positive cells were localized in the dorsal NT, DRG, in the myenteric region of the small intestine and the segmental nerves of the tail (Figure 1b). At the same A–P level of the E12.5 *Wnt1-Cre/R26R/enb5* embryos, only very faint X-gal staining was detected in the dorsal NT and there was no X-gal staining in the DRG (Figure 1b). Furthermore, the DRG in *Wnt1-Cre/R26R/enb5* was smaller than that in *Wnt1-Cre/R26R*. Reduced X-gal staining was also observed in the myenteric region of the small intestine in *Wnt1-Cre/R26R/enb5*.

NCC-derived melanoblasts were present between the skin epidermis and the dermis in *Wnt1-Cre/R26R* at E12.5 (Figure 2b; arrowheads), but not in *Wnt1-Cre/R26R/enb5*.

**Defects in cranial, sympathetic and DRG in *Wnt1-Cre/enb5*.** Glia and neuronal differentiation in the cranial, sympathetic and DRG in *enb5* and *Wnt1-Cre/enb5* embryos were analyzed using *Sox10* (NCC and glia marker) and *Islet1/2* (neuron marker). Both transcripts were detected in the trigeminal ganglion, facio-acoustic ganglion, glossopharyngeal ganglion, vagus ganglion, otic vesicle, sympathetic ganglion and DRG in both *enb5* and *Wnt1-Cre/enb5* at E9.5 and E10.5 (Figures 1c and d). The temporal and spatial expression patterns of *Sox10* and *Islet1/2* in the cranial, sympathetic and DRG were comparable, but the intensity was lower in *Wnt1-Cre/enb5*, in which *Hoxb5* signaling was perturbed in all NCC.

We determined the total volume of the DRG from 300 consecutive transverse sections from the trunk level (between the forelimb bud and the hindlimb bud) of E11.5 *enb5* and *Wnt1-Cre/enb5* embryos. The average volume of DRG in *Wnt1-Cre/enb5* was only one-quarter of that in *enb5* (Figure 1f). Immunostaining showed *Islet1/2* protein expression in neurons in the DRG and the lateral motor column of *enb5* and *Wnt1-Cre/enb5* mice (Figure 1e); however, the DRG was markedly smaller in *Wnt1-Cre/enb5*. In both genotypes, the percentages of neurons in DRG were comparable (*Wnt1-Cre/enb5* 68.5 ± 5.2% (mean ± S.D.), *enb5* 73.3 ± 2.9% (mean ± S.D.; Figure 1f), suggesting that the shrinkage of DRG was not solely attributable to loss of neurons.

**Defects in skin melanoblasts in *Wnt1-Cre/enb5*.** Trunk NCCs migrate dorsal-laterally between the surface ectoderm and dorsal surface of the somites, then differentiate into melanoblasts expressing melanin-producing enzyme dopachrome tautomerase (*Dct*). These melanoblasts are precursors of pigment cells in skin and iris of the eye. In *enb5* embryos, at E9.5, a cluster of *Dct*-positive melanoblasts appeared at the cervical region posterior to the otic vesicle (Figure 2a). By E10.5, this cervical cluster dispersed and migrated ventrally, populating the branchial arches and anterior trunk (Figure 2a). Strong *Dct* expression was also detected in the developing eye and the telecephalon. In *Wnt1-Cre/enb5* embryos, there was a drastic reduction in the number of *Dct*-expressing melanoblasts in the cervical region at E9.5 (Figure 2a). By E10.5, fewer melanoblasts had populated the branchial arches, and there were no detectable melanoblasts in the anterior trunk region (Figure 2a). In contrast, *Dct* expression in the developing eye and in the telecephalon in *Wnt1-Cre/enb5* embryos was comparable to that in *enb5* embryos. This absence of melanoblasts during early development led to skin hypopigmentation in *Wnt1-Cre/enb5* mice at postnatal day 3 when fur started to form (Figure 2c). By postnatal day 21, patches of white fur were obvious (Figure 2c). In adults, melanocytes were detected in the hair follicles in *Wnt1-Cre/R26R* and in the hair follicles of the skin with normal pigmentation in *Wnt1-Cre/enb5*, but not in the hair follicles in the white patches (Figure 2d).

**Defects in ENS in *Wnt1-Cre/enb5*.** We investigated the colonization of the intestine by NCC using X-gal. By E12.5, X-gal-positive neuroblasts colonized the small intestine of both *Wnt1-Cre/R26R* and *Wnt1-Cre/R26R/enb5* embryos

(Figure 1b). However, the intensity in the small intestine was lower in *Wnt1-Cre/R26R/enb5*, which indicated that there were fewer neuroblasts. By E16.5, neuroblasts had completed populating the entire gut, reaching the end of the colon in *Wnt1-Cre/R26R* embryos (Figure 2e). In contrast, in five out of six *Wnt1-Cre/R26R/enb5* embryos of the same litter, the neuroblasts had colonized only as far as the cecum, or up to half of the length or anterior two-thirds of the colon (Figure 2e). This defective colonization of the intestine by neuroblasts resulted in ENS anomaly in postnatal mice. At P28, a phenotype of megacolon, which resembled HSCR in humans, was observed in *Wnt1-Cre/enb5* (Figure 2f). Immunostaining for Tuj1 (a pan-neuronal marker) detected no enteric neurons in the distal part of the affected colon in *Wnt1-Cre/enb5*, whereas the proximal part was normally populated (Figure 2f).

In summary, disruption of *Hoxb5* signaling by *enb5* in NCC from the entire A–P axis of the NT resulted in multiple NCC-developmental defects including hypoplasia of cranial, sympathetic and DRG, hypopigmentation and ENS defects in mice.

**Hoxb5 function is required for the survival of vagal and trunk NCC.** The developmental defects observed in multiple NCC-derived lineages in *Wnt1-Cre/enb5* mice prompted us to examine whether the NCC population was depleted in these embryos. Using TUNEL assay, we detected apoptotic cells in the dorsal NT and the regions between the cardinal vein and dorsal aorta in the levels of both vagal and trunk regions in *Wnt1-Cre/enb5* at E9.5 and E10.5 (Figures 3b and d), whereas apoptotic cells were rarely detected in *enb5* embryos (Figures 3a and c). The majority of the apoptotic cells were immunostained for p75<sup>NTR</sup> (Figure 3e), a marker of NCC. Thus, blocking the activity of *Hoxb5* in NCC along the whole A–P axis of the NT leads to apoptosis of NCC. Apoptosis of NCC was also reported in mice nullified for *Sox9*.<sup>27</sup>

**Deletion of *Sox9* in *Wnt1-Cre* expressing cells resulted in vagal and trunk NCC apoptosis and developmental defects.** *Sox9* is a NCC marker and deletion of *Sox9* specifically in NCC by *Wnt1-Cre* system resulted in cell apoptosis in the ventral and dorsal NT, along the NCC migration pathways in E9.5 *Wnt1-Cre/Sox9<sup>flox/flox</sup>* embryos (Figure 4a). Apoptotic cells were not detected in *Sox9<sup>flox/flox</sup>* control littermates (Figure 4a).

In *Wnt1-Cre/R26R* embryos, X-gal-positive NCCs were found populating the trigeminal and facio-acoustic ganglion (arrows; Figure 4b), NT and DRG at E9.5; and sympathetic ganglia and DRG at E10.5 (Figure 4b). However, the blue staining in the corresponding structures at both stages of *Wnt1-Cre/R26R/Sox9<sup>flox/flox</sup>* embryos was relatively less

extensive and less intense (Figure 4b). We determined the total volume of the DRG from the trunk level (between the forelimb bud and the hindlimb bud) of E11.5 *Wnt1-Cre/Sox9<sup>flox/flox</sup>* and *Sox9<sup>flox/flox</sup>* embryos, and found that DRG volume in *Wnt1-Cre/Sox9<sup>flox/flox</sup>* was only 60% of that in *Sox9<sup>flox/flox</sup>* (Supplementary Figure 1A). The percentages of neurons in DRG in both genotypes were comparable (Supplementary Figure 1B), implying that, as in the conditional *Hoxb5* mutants, the shrinkage of DRG in the absence of *Sox9* activity was not solely attributable to loss of neurons.

We also investigated the migration of enteric neuroblasts and skin melanoblasts in *Wnt1-Cre/Sox9<sup>flox/flox</sup>* using X-gal staining. At E14.5, neuroblasts had colonized the entire gut and reached the distal colon in *Wnt1-Cre/R26R* (Figure 4c). In contrast, the neuroblasts had populated only up to the cecum and aganglionosis was observed in the distal colon of *Wnt1-Cre/R26R/Sox9<sup>flox/flox</sup>* embryos (Figure 4c).

The expression of *Dct* in the skin epidermis of *Wnt1-Cre/Sox9<sup>flox/flox</sup>* and *Sox9<sup>flox/flox</sup>* embryos at E10.5 was comparable in terms of both pattern and intensity (Figure 4d). By E12.5, melanoblasts were found between the epidermis and dermis of both *Wnt1-Cre/R26R/Sox9<sup>flox/flox</sup>* and *Wnt1-Cre/R26R* at the trunk level (compare Figures 4e and 2b), indicating that melanoblast development was largely unaffected by the *Sox9* deletion in NCC.

**Perturbation of *Hoxb5* function disrupts *Sox9* expression in NCC.** Blocking *Sox9* activity in NCC along the A–P axis of the NT leads to NCC apoptosis and developmental defects of DRG, sympathetic ganglion and ENS, which resemble most of the developmental defects observed when *Hoxb5* activity is blocked in the same regions. This suggested that *Hoxb5* and *Sox9* might function in the same developmental pathway.

To investigate the relationship between *Hoxb5* and *Sox9* in our mutants, we assessed *Sox9* expression. In E9.5 *enb5*, *Sox9*-expressing NCCs were localized in the dorsal NT, along the dorsal-lateral migration pathway under the surface ectoderm and ventral-medial migration pathway to the cardinal vein (Figure 5a). In contrast, in *Wnt1-Cre/enb5* mice, no *Sox9* immuno-positive NCCs were seen in the dorsal NT or under the surface ectoderm; and only a few *Sox9*-expressing NCCs were found in the vicinity of the cardinal vein (Figure 5b). These results suggested that *Sox9* might act downstream of *Hoxb5* in the same signaling pathway.


**HOXB5 binds to SOX9 promoter.** *In silico* analysis predicted three potential HOX-binding sites in the *SOX9* promoter: R1A (–483 to –466), R1B (–468 to –450) and R2 (–35 to –16) (Figure 6a). We evaluated the binding of


**Figure 1** Reduction of *LacZ*-expressing cells and shrinkage of DRG in *Wnt1-Cre/enb5* mice. (a) *LacZ*-expressing cells (stained blue) in *Wnt1-Cre/R26R* and *Wnt1-Cre/R26R/enb5* embryos (E9.0–E10.5) were localized by whole-mount X-gal staining for  $\beta$ -galactosidase. (b) X-gal-stained E12.5 embryos of *Wnt1-Cre/R26R* and *Wnt1-Cre/R26R/enb5* embryos were sectioned to reveal the spatial distribution of *LacZ*-expressing cells. Boxed regions were magnified and shown on the right. Arrowheads indicated the *LacZ*-expressing cells at the dorsal NT. DRG was demarcated with broken line. Expression of *Sox10* (purple; c) and *Islet1/2* (purple; d) in *enb5* and *Wnt1-Cre/enb5* embryos was analyzed by whole-mount *in situ* hybridization. (e) Expression of *Islet1/2* (green) on sections of E11.5 *enb5* and *Wnt1-Cre/enb5* embryos was analyzed by immunofluorescence. Dorsal root ganglion was demarcated with broken line. (f) Average total volume of DRG (mean  $\pm$  S.D.) from the trunk level of E11.5 *enb5* and *Wnt1-Cre/enb5* embryos was determined and compared. Volume of DRGs in *enb5* embryo was taken arbitrarily as 100%. Average % of *Islet1/2* immuno-positive neurons versus total number of cells (mean  $\pm$  S.D.) in DRG of E11.5 *enb5* and *Wnt1-Cre/enb5* embryos was determined and compared. Number of embryos analyzed was indicated by 'n'. ba, branchial arch; cr, circumpharyngeal ridge; drg, dorsal root ganglion; fa, facio-acoustic ganglion; fgt, foregut; gg, glossopharyngeal ganglion; li, liver; lmc, lateral motor column; lu, lung; mb, midbrain; nt, neural tube; ov, otic vesicle; sg, sympathetic ganglion; si, small intestine; sn, segmental nerve; t, tail; tg, trigeminal ganglion; vg, vagus ganglion



HOXB5 to the *SOX9* promoter using electro-mobility shift assay (EMSA) with a glutathione *S*-transferase (GST)-HOXB5 fusion protein and polymerase chain reaction

(PCR) products spanning these binding sequences (Figure 6a). A retarded band was observed only in the lanes containing the GST-HOXB5 and the PCR fragments (probe)







of R1 and R2. No retarded band was observed if GST-HOXB5 was replaced with GST protein, or if excess unlabeled probe was included in the reaction mixtures. More importantly, the specific binding between GST-HOXB5 and the probe was completely abolished if the respective HOX-binding sequence was deleted from the probe.


We extended this analysis by looking at the binding of HOXB5 to the *SOX9* promoter in a neuroblastoma cell line (SK-N-SH) transfected with *HOXB5*, using chromatin immunoprecipitation (ChIP) followed by quantitative PCR. Binding of HOXB5 to R1 and R2 was significantly enriched compared with the nonspecific IgG control (Figure 6b). Furthermore, we confirmed the binding of Hoxb5 to the *Sox9* promoter *in vivo* in the central nervous system (CNS) of E9.5 wild-type embryos (Figure 6c).

**HOXB5 trans-activation from SOX9 promoter is suppressed by *enb5*.** To study whether HOXB5 protein trans-activates the *SOX9* promoter, we used a luciferase reporter construct consisting of 1100 bp (−1034 to +67) of the *SOX9* gene 5' of the luciferase gene in SK-N-SH cells. HOXB5 increased the transcription by  $5.8 \pm 0.1$  (mean  $\pm$  S.D.) fold compared with the pRC/CMV control (Figure 6d). Deletion of R1A and R1B from the *SOX9* promoter reduced the induction (to  $4.98 \pm 0.10$  and  $3.61 \pm 0.20$  (mean  $\pm$  S.D.) fold, respectively). Conversely, deletion of R2 increased the induction to  $13.52 \pm 1.52$  (mean  $\pm$  S.D.) fold. Our data revealed that binding of HOXB5 to these elements of the *SOX9* promoter increases overall transcription from the *SOX9* promoter, which could be attributed to the differential binding of HOXB5 onto R1 to R2.

Transfection of the dominant-negative form of Hoxb5, *enb5*, prominently suppressed the trans-activation of *SOX9* by HOXB5 (Figure 6e). To test the mechanism, we generated a vector expressing a Flag-tagged *enb5* (Flag-*enb5*). As expected, Flag-*enb5* suppressed HOXB5-transactivated *SOX9* promoter activity by 50% (Figure 6e). ChIP and quantitative PCR analysis revealed a modest but significant enrichment ( $1.98 \pm 0.08$  and  $1.25 \pm 0.06$  (mean  $\pm$  S.E.M.) fold for R1 and R2, respectively) of binding of Flag-*enb5* to the *SOX9* promoter compared with a nonspecific IgG control. This suggested that Flag-*enb5*, thus *enb5*, binds to the same regions of the *SOX9* promoter as HOXB5 (Figure 6f). Therefore, HOXB5 binds to the *SOX9* promoter and this can be suppressed by the dominant-negative chimera, *enb5*.

**Sox9 alleviates *enb5*-induced cell death and Hoxb5 induces Sox9 expression *in ovo*.** *In ovo* electroporation of chick NT with *enb5* resulted in obvious cell death in the

transfected region but only a few apoptotic cells were detected in the contralateral non-electroporated side. Co-electroporation of *Hoxb5* or *Sox9* notably reduced




**Figure 3** Apoptosis of NCCs in *Wnt1-Cre/enb5* mice. (a–d) TUNEL staining was performed to localize apoptotic cells (green) on *Wnt1-Cre* or *enb5* embryos and *Wnt1-Cre/enb5* sections of the trunk level. Boxed regions were magnified and shown as insets. (e) Section of E9.5 *Wnt1-Cre/enb5* embryo was examined by TUNEL staining (green) and immunofluorescence (red) using anti-p75<sup>NTR</sup> serum. Number of embryos analyzed was indicated by 'n'. cv, cardinal vein; da, dorsal aorta; ht, heart; pe, pharyngeal ectoderm

**Figure 2** Skin hypopigmentation and defective ENS development in *Wnt1-Cre/enb5* mice. (a) Melanoblasts in *enb5* and *Wnt1-Cre/enb5* embryos were localized by *in situ* hybridization for *Dct* (purple). Regions highlighted with dotted line were magnified and shown on the right. (b) NCC-derived melanoblasts (stained blue; arrowheads) in *Wnt1-Cre/R26R* and *Wnt1-Cre/R26R/enb5* embryos were localized by X-gal staining. (c) At postnatal day 3 (P3), areas of fur without pigment were observed in *Wnt1-Cre/enb5* (*mut*) mice. Fur was properly pigmented in *enb5* (*ctrl*) littermates. At postnatal day 21 (P21), *Wnt1-Cre/enb5* mice developed skin hypopigmentation. (d) NCC-derived melanocytes (stained blue) in adult *Wnt1-Cre/R26R* and *Wnt1-Cre/R26R/enb5* mouse skin were localized by X-gal staining. Hair follicles were demarcated with broken line. (e) Enteric neuroblasts (stained blue) in the developing gut of E16.5 *Wnt1-Cre/R26R* and *Wnt1-Cre/R26R/enb5* embryos were localized by X-gal staining. Dotted regions were magnified and shown as insets. The number of gastrointestinal tract showing different extents of colonization of enteric neuroblasts was indicated by 'n'. (f) Guts of P28 *enb5* and *Wnt1-Cre/enb5* mice were dissected for morphological examination. The proximal colon of *Wnt1-Cre/enb5* mice was swollen but the distal colon was constricted. Sections of the proximal and distal colons of *enb5* and *Wnt1-Cre/enb5* mice were immunostained (green) for Tuj1 to localize enteric neurons. The levels from which the transverse sections were analyzed were indicated by 'a' and 'b'. Number of gut tissues, embryos or mice analyzed was indicated by 'n'. ce, cecum; cm, circular muscle; co, colon; der, dermis; e, eye; epi, epidermis; mu, mucosa; lm, longitudinal muscle; ov, otic vesicle; st, stomach; si, small intestine

enb5-induced cell death (Figure 7a), again suggesting that *Sox9* and *Hoxb5* act in the same signaling pathway. When chick NT was electroporated with *Hoxb5*, ectopic expression

of *Sox9* was induced on the transfected side at 6–12h, confirming the trans-activation action of *Sox9* by *Hoxb5* (Figure 7b).



**Figure 4** Apoptosis of NCCs and defective development of NCC-derived structures in *Wnt1-Cre/Sox9<sup>flox/flox</sup>* mice. (a) TUNEL staining on E9.5 *Sox9<sup>flox/flox</sup>* and *Wnt1-Cre/Sox9<sup>flox/flox</sup>* embryo sections of the trunk level was performed to localize apoptotic cells (green). (b and c) NCC-derived cells (stained blue) in embryos (b) and gut (c) of *Wnt1-Cre/R26R* and *Wnt1-Cre/R26R/Sox9<sup>flox/flox</sup>* mice were localized by X-gal staining. (d) Melanoblasts (purple) were localized by *in situ* hybridization for *Dct* in E10.5 *Sox9<sup>flox/flox</sup>* and *Wnt1-Cre/Sox9<sup>flox/flox</sup>* embryos. Regions highlighted were magnified and shown on the right. (e) NCC-derived melanoblasts (stained blue; arrowheads) on section of *Wnt1-Cre/Sox9<sup>flox/flox</sup>* embryos were localized by X-gal staining. Number of embryos analyzed was indicated by 'n'. ba, branchial arch; ce, cecum; co, colon; cv, cardinal vein; da, dorsal aorta; der, dermis; drg, dorsal root ganglion; e, eye; epi, epidermis; ht, heart; nt, neural tube; se, surface ectoderm; sg, sympathetic ganglion; st, stomach; si, small intestine; te, telecephalon



## Discussion

In this study, we used mice expressing a dominant-negative form of Hoxb5 (*enb5*) in NCC from all along the NT to investigate the impact of abnormal Hoxb5 signaling in the development of NCC-derived tissues. These *Wnt1-Cre/enb5* mice displayed defects in multiple NCC-derived tissues, suggesting that NCCs were affected before lineage specification. TUNEL analysis revealed that pre-migratory and migratory NCC underwent apoptosis in E9.5 *Wnt1-Cre/enb5* embryos. Taken together, our previous report<sup>22</sup> and this study indicate that Hoxb5 regulates the survival of vagal and trunk NCC.

In mouse embryos, vagal NCCs enter the foregut at E9.5 and colonize the gut reaching distal hindgut at E14.5. During migration, NCCs proliferate, interact with gut mesenchyme, and differentiate into neurons and glia. NCC growth defects and errors in their interactions with gut mesenchyme contribute to abnormal ENS.<sup>28,29</sup> In *Wnt1-Cre/enb5* embryos, expression of *enb5* by *Wnt1-Cre* led to apoptosis of pre-migratory and early migratory NCC. Expression of *enb5* in vagal NCC by another *Cre* mouse (*b3-IIIa-Cre*) resulted in NCC migration defect in the intestine.<sup>22</sup> In *b3-IIIa-Cre/enb5* mice, *enb5*-expressing neuroblasts survive, proliferate and differentiate normally in the intestine, and NCC apoptosis was not observed. The lack of NCC apoptosis in *b3-IIIa-Cre/enb5* embryos is attributed to a more restricted and late expression of *enb5* in *b3-IIIa-Cre/enb5*<sup>22</sup> than that in *Wnt1-Cre/enb5*. All these indicate that the differentiation and proliferation of neuroblasts in the intestine is largely unaffected by *enb5*. ENS defect in *Wnt1-Cre/enb5* mice is mainly attributed to NCC apoptosis, which leads to reduction of the population size of the NCC entering the gut. Whether *enb5* affects NCC formation requires further investigation. *Hoxb5* is also expressed in gut mesenchyme, suggesting it may influence the gut environment.<sup>17</sup> However, *enb5* is only expressed in NCC in this and previous<sup>22</sup> studies, indicating that ENS anomalies in these mice are due to defective NCC growth.


*Sox9* is required for NCC development, and we have demonstrated that blocking Hoxb5 downregulated *Sox9* expression in these cells. HOXB5 binds to *SOX9* promoter and induces *SOX9* expression, and this induction of *SOX9* promoter activity was substantially reduced by *enb5*. The human and mouse *Sox9* promoters share high sequence conservation (>70%), and Hoxb5-binding sites were also identified within the mouse *Sox9* promoter (Supplementary Figure 2). ChIP assay on CNS confirmed that Hoxb5 bound to the mouse *Sox9* promoter. More importantly, expression of *enb5* in NCC reduced *Sox9* expression in pre-migratory and migratory NCC in *Wnt1-Cre/enb5* embryos. Our findings revealed that apoptosis of trunk NCC and defects in multiple trunk NCC-derived tissues in *Wnt1-Cre/enb5* were consequences of downregulated *Sox9* expression in NCC.

*Wnt1-Cre/Sox9<sup>fllox/fllox</sup>* mice displayed craniofacial defects resembling campomelic dysplasia in human.<sup>30</sup> Cranial NCC-derived cartilages and endochondral bones of the head were completely absent in *Wnt1-Cre/Sox9<sup>fllox/fllox</sup>* mice, but development of trunk NCC-derived structures was not addressed. *Wnt1-Cre/enb5* mice also display domed skull and short snout

as *Wnt1-Cre/Sox9<sup>fllox/fllox</sup>* mice, but the cranial NCC-derived skeletal elements are not absent but malformed in *Wnt1-Cre/enb5* heads (unpublished data). Different fates of NCC are dictated by both the intrinsic properties and external environmental factors. Trunk NCCs show overlapping *Hoxb5* and *Sox9* expression pattern and they committed to apoptosis when there is a loss of *Hoxb5* or *Sox9* functions in respective mutant mice. However, in cranial NCC, the expression patterns of *Hoxb5*<sup>20,21,24</sup> and *Sox9*<sup>31,32</sup> in mice are not completely overlapping, which indicates that Hoxb5 alone is neither sufficient nor essential for *Sox9* expression. Moreover, the apoptotic patterns seen in the developing heads of *Wnt1-Cre/Sox9<sup>fllox/fllox</sup>* and *Wnt1-Cre/enb5* mice were not exactly the same too (unpublished data). These suggested that the regulation of Hoxb5 on *Sox9* in trunk NCC may not be identical to that in cranial NCC. Therefore, it is not totally unexpected to observe phenotypic differences in some NCC-derived tissues between *Wnt1-Cre/Sox9<sup>fllox/fllox</sup>* and *Wnt1-Cre/enb5* mice, and *Sox9* deletion or *enb5* expression by *Wnt1-Cre* may affect different developmental aspects of cranial NCC.

*Sox9* provides the competence for trunk NCC to migrate from the NT; it is also required for NCC survival.<sup>27</sup> However, not all the trunk NCC died in *Sox9<sup>-/-</sup>* mutants, as some NCC-derived neuro-glial components were still present in the DRG and peripheral nerve as shown by the residual expression of Brn3.0 (neuron marker) and Sox10 (glia marker),<sup>27</sup> indicating that the generation and survival of a subpopulation of trunk NCC was independent of *Sox9* function.

*Wnt1-Cre/enb5* and *Wnt1-Cre/Sox9<sup>fllox/fllox</sup>* mutants display some common phenotypes including NCC apoptosis, defective ENS, reduction of DRG and sympathetic ganglia, however, the pigmentation defect was observed only in *Wnt1-Cre/enb5*. The ENS defects in *Wnt1-Cre/Sox9<sup>fllox/fllox</sup>* mutants denoted that *Sox9* was also required for vagal NCC development in addition to its inductive and survival roles in trunk NCC. In mouse, trunk NCCs migrate to their target organs in three waves: the first two migrate ventral-medially to



**Figure 5** Reduction of *Sox9* expression in *Wnt1-Cre/enb5* mice. (a and b) *Sox9*-expressing cells (green; arrows) were localized in E9.5 *Wnt1-Cre* or *enb5* (a) and *Wnt1-Cre/enb5* (b) embryos by immunofluorescence using anti-*Sox9* serum on sections of the trunk level. Regions highlighted were magnified and shown as insets. Arrowhead denoted the notochord. Number of embryos analyzed was indicated by 'n'. cv, cardinal vein; da, dorsal aorta; ht, heart; nt, neural tube






Another *SoxE* gene, *Sox10*, is essential for the specification of NCC into melanoblast and glia cells.<sup>34–37</sup> *In silico* analysis identified potential Hox-binding sites in the *Sox10* promoter (unpublished data), future investigation could address the relationship between *Hoxb5*, *Sox10* and pigmentation defect in *Wnt1-Cre/enb5* mice.

Hirschsprung disease (HSCR, MIM142623) is a neurocristopathy of ENS deficiency, characterized by the absence of enteric ganglia from variable lengths of the gut. Approximately 30% of HSCR patients exhibit additional NCC-associated anomalies, known as syndromic

HSCR.<sup>28,38–40</sup> Mutations in *SOX10*, *EDN3* or *EDNRB* have been identified to be responsible for 65–85% of the syndromic HSCR cases with pigmentation defects, whereas genes responsible for the remaining cases still left undetermined.<sup>41</sup> Especially for *EDN3*, a reduction in spinal sensory innervation of the rectum was reported in mice with disruption of *Edn3* gene expression.<sup>42</sup> In line with this, this study also showed that perturbation of *Hoxb5* function in NCC of mice causes multiple neurological phenotypes and hypopigmentation, resembling some of the phenotypes of syndromic HSCR. Nevertheless, the causal relationship



**Figure 7** Sox9 alleviates *enb5*-induced cell death and *Hoxb5* induces *Sox9* expression in chick NT. (a) *In ovo* electroporation with *enb5*, *Hoxb5* and *Sox9*, either alone or in combination. Chick NT was assayed for TUNEL (red) and immunofluorescence for GFP (green) 24 h post-transfection on transverse sections at trunk level. Number of embryos analyzed was indicated by 'n'. (b) *In ovo* electroporation with chick *Hoxb5*, chick NT was assayed for GFP (green) and *Sox9* expression (purple) 12 h post-transfection by immunofluorescence for GFP (green) and *in situ* hybridization for *Sox9* (purple) on transverse sections at trunk level. (n/n) indicated number of embryos showing positive detection (GFP or *Sox9*) versus number of transfected embryos. (c) Schematic diagram of the HH10-11 chick embryo 12–24 h after electroporation, dotted line indicated the level of sections used for immunofluorescence or *in situ* hybridization analysis

between abnormal *HOXB5* function and HSCR in human deserves further investigation, in particular, the identification of a dominant-negative type of *HOXB5* mutation in these patients.

### Materials and Methods

**Mouse lines.** The *enb5*<sup>22</sup>, *R26R*<sup>43</sup>, *Sox9*<sup>lox/lox44</sup> and *Wnt1-Cre*<sup>26</sup> mice were maintained on mixed genetic backgrounds. Genotyping of mice was performed by PCR (Supplementary Information). All experimental procedures were approved by the Committee on the Use of Live Animals at the University of Hong Kong (CULTRA 2038-009).

**Immunofluorescence staining.** Immunofluorescence staining was performed according to standard protocol. Antibodies used were: *Isl1/2* (Developmental Studies Hybridoma Bank, Iowa City, IA, USA; 51.4H9, 1:100); *Sox9* (Chemicon, Billerica, MA, USA; ab5535, 1:500); GFP (AbDirect, Oxford, UK; 4745–1051, 1:1000).

**TUNEL assay and immunofluorescence staining.** Apoptotic cells on sections detected using *In Situ* Cell Death Detection Kit (Roche Applied Science, Indianapolis, IN, USA). After TUNEL, sections were incubated with antibody for GFP (AbDirect, 4745–1051, 1:1000) or p75<sup>NTR</sup> (Chemicon, 07–476, 1:2000). Images were taken with Nikon Eclipse 80i microscope (Melville, NY, USA) mounted with SPOT RT3 microscope digital camera (DIAGNOSTIC Instruments, Inc., Sterling Heights, MI, USA). Photos were compiled using Adobe Photoshop 7.

**Determination of the sizes of DRG in embryos.** Transverse sections (10  $\mu$ m in thickness) from the trunk level (between the forelimb bud and the hindlimb bud) were mounted onto glass slides, stained with hematoxylin and eosin. Photos of 300 consecutive sections of each embryo were taken at 100 $\times$  on a Nikon Eclipse E600 microscope (Tokyo, Japan) fitted with Sony Digital Camera DSM1200F (Tokyo, Japan). DRG on either side of the NT in the photos were demarcated manually. The area of DRG on each section was determined using the software ImageJ (NIH, Bethesda, MD, USA) and an arbitrary value was given. The volume of DRG on each section was then determined by multiplying the total area of the DRG (on each side of the NT) by 10 (each section was of 10  $\mu$ m in thickness).

**In situ hybridization.** *In situ* hybridization was performed on whole embryos to detect the expression of *Sox10* and *Isl1/2* as previously described.<sup>45</sup>

**Electro-mobility shift assay.** PCR products spanning the putative HOX-binding sites of the human *SOX9* promoter were labeled with Biotin-11-UTP (Pierce, Thermo Fisher Scientific, Rockland, MA, USA), EMSA was performed as previously described.<sup>46</sup>

**ChIP and quantitative PCR assay.** ChIP assay on human neuroblastoma cell line SK-N-SH (#HTB-11) (ATCC, Manassas, VA, USA) transfected with *HOXB5* or *Flag-enb5* was performed as previously described.<sup>46</sup> ChIP assay on mouse developing CNS was performed with head and NT tissues from 27 E9.5 WT mouse embryos with minor modifications.<sup>46,47</sup> See Supplementary Information for quantitative PCR primers for human and mouse *Sox9* promoters.

### Transient transfection and dual-luciferase reporter assay.

A *SOX9*-luciferase reporting construct containing the 1100 bp (–1034 to +36) DNA fragment of the human *SOX9* promoter<sup>48</sup> and the *luciferase* gene was used for the study. Mutated *SOX9*-luciferase constructs with the predicted HOX-binding sites deleted were generated using QuikChange Site-Directed Mutagenesis Kit (Stratagene, Santa Clara, CA, USA). The dual-luciferase reporter assay was performed as previously described.<sup>46</sup> At least two independent triplicate or quintuplicate experiments were performed, and the luciferase activity was presented as relative luciferase unit normalized with the Renilla luciferase internal control.

**Chick in ovo electroporation.** *Enb5* and chick *Hoxb5* were cloned into *pCIG* expression vector,<sup>49</sup> upstream of an internal ribosomal entry site (IRES) and a nuclear localization sequence-tagged enhanced green fluorescent protein (EGFP). HH10-11 chick embryos (SIPAFASI, Jinan, China) were electroporated with *Hoxb5*, *enb5* or *Sox9*<sup>50</sup> (4  $\mu$ g/ $\mu$ l) either alone or in combination. *pCAGGS*-

*IREs-nls-EGFP* (*pCIG*) was co-injected at a concentration of 1  $\mu$ g/ $\mu$ l to monitor the injection and electroporation.

**Statistical analyses.** ANOVA was performed for all experiments to calculate the differences between groups, and *P*-value <0.05 was regarded as statistical significant.

### Conflict of Interest

The authors declare no conflict of interest.

**Acknowledgements.** Plasmids for riboprobe synthesis were provided as gifts: *Dct* (I Jackson, MRC Human Genetics Unit, Western General Hospital, Edinburgh); *Isl1/2* (R Lovell-Badge, MRC NIMR, London, UK); chick *Sox9* (PT Sharpe, King's College, London, UK); and *Sox10* (M Tani, National Cancer Center Research Institute, Japan). The *SOX9*-luciferase construct was provided by S Piera (Thomas Jefferson University, Philadelphia, PA, USA). Mouse strains used in this study were provided as gifts: *R26R* (PM Soriano, Mount Sinai School of Medicine), *Sox9*<sup>lox/lox</sup> (A Schedl and M-C Chaboissier, Centre de Biochimie, Parc Valrose, France), *Wnt1-Cre* (AP McMahon, Harvard University, USA). We thank Patrick Tam for comments on the manuscript, and J Marsh for proofreading the manuscript. This work was partly supported by the Hong Kong RGC GRF (HKU 7245/02M) and HKU Seed Funding for Basic Research (200811159088) to VCH Lui.

- Kalchauer C, Le Douarin N. *The Neural Crest*. Cambridge University Press: Cambridge, UK, 1999.
- Le Douarin NM, Creuzet S, Couly G, Dupin E. Neural crest cell plasticity and its limits. *Development* 2004; **131**: 4637–4650.
- Sauka-Spengler T, Bronner-Fraser M. A gene regulatory network orchestrates neural crest formation. *Nat Rev Mol Cell Biol* 2008; **9**: 557–568.
- Anderson RB, Stewart AL, Young HM. Phenotypes of neural-crest-derived cells in vagal and sacral pathways. *Cell Tissue Res* 2006; **323**: 11–25.
- Burns AJ, Douarin NM. The sacral neural crest contributes neurons and glia to the post-umbilical gut: spatiotemporal analysis of the development of the enteric nervous system. *Development* 1998; **125**: 4335–4347.
- Kapur RP. Colonization of the murine hindgut by sacral crest-derived neural precursors: experimental support for an evolutionarily conserved model. *Dev Biol* 2000; **227**: 146–155.
- Nagy N, Brewer KC, Mwirerwa O, Goldstein AM. Pelvic plexus contributes ganglion cells to the hindgut enteric nervous system. *Dev Dyn* 2007; **236**: 73–83.
- Serbedzija GN, Burgan S, Fraser SE, Bronner-Fraser M. Vital dye labelling demonstrates a sacral neural crest contribution to the enteric nervous system of chick and mouse embryos. *Development* 1991; **111**: 857–866.
- Wang X, Chan AK, Sham MH, Burns AJ, Chan WY. Analysis of the sacral neural crest cell contribution to the hindgut enteric nervous system in the mouse embryo. *Gastroenterology* 2011; **141**: 992–1002; e1–6.
- Akin ZN, Nazarali AJ. Hox genes and their candidate downstream targets in the developing central nervous system. *Cell Mol Neurobiol* 2005; **25**: 697–741.
- Carpenter EM. Hox genes and spinal cord development. *Dev Neurosci* 2002; **24**: 24–34.
- Duboule D, Morata G. Colinearity and functional hierarchy among genes of the homeotic complexes. *Trends Genet* 1994; **10**: 358–364.
- Durston AJ, Jansen HJ, In der Rieden P, Hooiveld MH. Hox collinearity—a new perspective. *Int J Dev Biol* 2011; **55**: 899–908.
- Lumsden A, Krumlauf R. Patterning the vertebrate neuraxis. *Science* 1996; **274**: 1109–1115.
- Trainor PA, Krumlauf R. Patterning the cranial neural crest: hindbrain segmentation and Hox gene plasticity. *Nat Rev Neurosci* 2000; **1**: 116–124.
- Trainor PA, Manzanares M, Krumlauf R. Genetic interactions during hindbrain segmentation in the mouse embryo. *Results Probl Cell Differ* 2000; **30**: 51–89.
- Fu M, Lui VC, Sham MH, Cheung AN, Tam PK. *HOXB5* expression is spatially and temporally regulated in human embryonic gut during neural crest cell colonization and differentiation of enteric neuroblasts. *Dev Dyn* 2003; **228**: 1–10.
- Hogan BL, Holland PW, Lumsden A. Expression of the homeobox gene, *Hox 2.1*, during mouse embryogenesis. *Cell Differ Dev* 1988; **25**(Suppl): 39–44.
- Holland PW, Hogan BL. Spatially restricted patterns of expression of the homeobox-containing gene *Hox 2.1*. during mouse embryogenesis. *Development* 1988; **102**: 159–174.
- Krumlauf R, Holland PW, McVey JH, Hogan BL. Developmental and spatial patterns of expression of the mouse homeobox gene, *Hox 2.1*. *Development* 1987; **99**: 603–617.
- Kuratani SC, Wall NA. Expression of *Hox 2.1* protein in restricted populations of neural crest cells and pharyngeal ectoderm. *Dev Dyn* 1992; **195**: 15–28.



22. Lui VC, Cheng WW, Leon TY, Lau DK, Garcia-Barcelo MM, Miao XP *et al*. Perturbation of hoxb5 signaling in vagal neural crests down-regulates ret leading to intestinal hypoganglionosis in mice. *Gastroenterology* 2008; **134**: 1104–1115.
23. Pitera JE, Smith VV, Thorogood P, Milla PJ. Coordinated expression of 3' hox genes during murine embryonal gut development: an enteric Hox code. *Gastroenterology* 1999; **117**: 1339–1351.
24. Wall NA, Jones CM, Hogan BL, Wright CV. Expression and modification of Hox 2.1 protein in mouse embryos. *Mech Dev* 1992; **37**: 111–120.
25. Rancourt DE, Tsuzuki T, Capecchi MR. Genetic interaction between hoxb-5 and hoxb-6 is revealed by nonallelic noncomplementation. *Genes Dev* 1995; **9**: 108–122.
26. Danielian PS, Muccino D, Rowitch DH, Michael SK, McMahon AP. Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase. *Curr Biol* 1998; **8**: 1323–1326.
27. Cheung M, Chaboissier MC, Mynett A, Hirst E, Schedl A, Briscoe J. The transcriptional control of trunk neural crest induction, survival, and delamination. *Dev Cell* 2005; **8**: 179–192.
28. Amiel J, Sproat-Emison E, Garcia-Barcelo M, Lantieri F, Burzynski G, Borrego S *et al*. Hirschsprung disease, associated syndromes and genetics: a review. *J Med Genet* 2008; **45**: 1–14.
29. Tam PK, Garcia-Barcelo M. Genetic basis of Hirschsprung's disease. *Pediatr Surg Int* 2009; **25**: 543–558.
30. Mori-Akiyama Y, Akiyama H, Rowitch DH, de Crombrughe B. Sox9 is required for determination of the chondrogenic cell lineage in the cranial neural crest. *Proc Natl Acad Sci USA* 2003; **100**: 9360–9365.
31. Morais da Silva S, Hacker A, Harley V, Goodfellow P, Swain A, Lovell-Badge R. Sox9 expression during gonadal development implies a conserved role for the gene in testis differentiation in mammals and birds. *Nat Genet* 1996; **14**: 62–68.
32. Wright E, Hargrave MR, Christiansen J, Cooper L, Kun J, Evans T *et al*. The Sry-related gene Sox9 is expressed during chondrogenesis in mouse embryos. *Nat Genet* 1995; **9**: 15–20.
33. Ruhrberg C, Schwarz Q. In the beginning: generating neural crest cell diversity. *Cell Adh Migr* 2010; **4**: 622–630.
34. Paratore C, Goerich DE, Suter U, Wegner M, Sommer L. Survival and glial fate acquisition of neural crest cells are regulated by an interplay between the transcription factor Sox10 and extrinsic combinatorial signaling. *Development* 2001; **128**: 3949–3961.
35. Potter SB, Furumura M, Dunn KJ, Arnheiter H, Pavan WJ. Transcription factor hierarchy in Waardenburg syndrome: regulation of MITF expression by SOX10 and PAX3. *Hum Genet* 2000; **107**: 1–6.
36. Potter SB, Mollaaghababa R, Hou L, Southard-Smith EM, Hornyak TJ, Arnheiter H *et al*. Analysis of SOX10 function in neural crest-derived melanocyte development: SOX10-dependent transcriptional control of dopachrome tautomerase. *Dev Biol* 2001; **237**: 245–257.
37. Southard-Smith EM, Kos L, Pavan WJ. Sox10 mutation disrupts neural crest development in Dom Hirschsprung mouse model. *Nat Genet* 1998; **18**: 60–64.
38. Bonnet JP, Till M, Ebery P, Attie T, Lyonnet S. Waardenburg-Hirschsprung disease in two sisters: a possible clue to the genetics of this association? *Eur J Pediatr Surg* 1996; **6**: 245–248.
39. Toki F, Suzuki N, Inoue K, Suzuki M, Hirakata K, Nagai K *et al*. Intestinal aganglionosis associated with the Waardenburg syndrome: report of two cases and review of the literature. *Pediatr Surg Int* 2003; **19**: 725–728.
40. Yoder BJ, Prayson RA. Shah-Waardenburg syndrome and Dandy-Walker malformation: an autopsy report. *Clin Neuropathol* 2002; **21**: 236–240.
41. Pingault V, Ente D, Dastot-Le Moal F, Goossens M, Marlin S, Bondurand N. Review and update of mutations causing Waardenburg syndrome. *Hum Mutat* 2010; **31**: 391–406.
42. Zagorodnyuk VP, Kylah M, Nicholas S, Peiris H, Brookes SJ, Chen BN *et al*. Loss of visceral pain following colorectal distension in an endothelin-3 deficient mouse model of Hirschsprung's disease. *J Physiol* 2011; **589**: 1691–1706.
43. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat Genet* 1999; **21**: 70–71.
44. Akiyama H, Chaboissier MC, Behringer RR, Rowitch DH, Schedl A, Epstein JA *et al*. Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. *Proc Natl Acad Sci USA* 2004; **101**: 6502–6507.
45. Cheng Y, Cheung M, Abu-Elmagd MM, Orme A, Scotting PJ. Chick sox10, a transcription factor expressed in both early neural crest cells and central nervous system. *Brain Res Dev Brain Res* 2000; **121**: 233–241.
46. Zhu J, Garcia-Barcelo MM, Tam PK, Lui VC. HOXB5 cooperates with NKX2-1 in the transcription of human RET. *PLoS One* 2011; **6**: e20815.
47. Liu W, Lagutin OV, Mende M, Streit A, Oliver G. Six3 activation of Pax6 expression is essential for mammalian lens induction and specification. *EMBO J* 2006; **25**: 5383–5395.
48. Piera-Velazquez S, Hawkins DF, Whitecavage MK, Colter DC, Stokes DG, Jimenez SA. Regulation of the human SOX9 promoter by Sp1 and CREB. *Exp Cell Res* 2007; **313**: 1069–1079.
49. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* 1991; **108**: 193–199.
50. Cheung M, Briscoe J. Neural crest development is regulated by the transcription factor Sox9. *Development* 2003; **130**: 5681–5693.

Supplementary Information accompanies this paper on Cell Death and Differentiation website (<http://www.nature.com/cdd>)